PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Oral administration of C. vulgare extract (100 mg/kg) effectively mitigated scopolamine-induced memory impairment in male Wistar rats [PMID:38339117].
Aqueous extracts showed strong antitumor activity against human metastatic melanoma (A2058), epidermoid carcinoma of the larynx (HEp-2), and mouse lymphoma (L5178Y) cell lines [PMID:11995932]. Methanolic extracts were active against the MCF-7 cell line [PMID:12748981].
Extracts demonstrated strong antibacterial action against both gram-positive and gram-negative microorganisms, including multi-resistant urocultures [PMID:10071825].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 37111815 (2023) — Antitumor and Antioxidant Activities of In Vitro Cultivated and Wild-Growing Clinopodium vulgare L. Plants. · Plants (Basel, Switzerland)
- 2.PMID: 30481570 (2019) — Clinopodium vulgare L. (wild basil) extract and its active constituents modulate cyclooxygenase-2 expression in neutrophils. · Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
- 3.PMID: 38312627 (2024) — Exploring nature's hidden treasure: Unraveling the untapped phytochemical and pharmacological potentials of Clinopodium vulgare L. - A hidden gem in the Lamiaceae family. · Heliyon
- 4.PMID: 38339117 (2024) — Extracts of Sideritis scardica and Clinopodium vulgare Alleviate Cognitive Impairments in Scopolamine-Induced Rat Dementia. · International journal of molecular sciences
- 5.PMID: 35357745